REPEAT – Irwin Naturals Acquires Ketamine Media
March 22, 2023
Ryan Allway March 22nd, 2023 News, Top News Expanding Reach in Rapidly Growing Ketamine Therapy Market LOS ANGELES, March 22, 2023 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) is thrilled to announce the successful acquisition of Keta Media, LLC, dba Ketamine Media (“Ketamine... Read more
Irwin Naturals Signs Letter of Intent to Acquire Braxia Scientific
January 27, 2023
Ryan Allway January 27th, 2023 News, Top News Strategic transaction assembles an experienced management and scientific team world-renowned in mental health treatment, research and development Establishes large footprint of 17 specialized mental health clinics across North America, enhanced by a telehealth platform expected to extend access to critical treatments... Read more
Ryan Allway December 9th, 2022 Psychedelics, Top News Company continues to expand its national network of psychedelic mental-healthcare clinics LOS ANGELES, Dec. 09, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) completed the acquisition of the assets of Clare Clinic, Inc., d/b/a Florida... Read more
Ehave Shareholder from CEO Ben Kaplan and Corporate Update
December 7, 2022
Ryan Allway December 7th, 2022 Psychedelics, Top News MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan. Dear Fellow... Read more
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
December 1, 2022
Ryan Allway December 1st, 2022 Psychedelics, Top News ENGLEWOOD CLIFFS, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. ( Nasdaq: SILO ) (“the Company”) , a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today issued a letter to shareholders highlighting the Company’s progress and potential for its portfolio of... Read more
Ryan Allway August 23rd, 2022 Psychedelics, Top News Based on over 20 years of pioneering Yale University research, clinical development currently underway to create and develop viable and efficacious treatment alternatives for patients with major depressive disorder by leveraging the known pharmacology of ketamine and psychedelic-based therapeutics SAN FRANCISCO, August... Read more
Ryan Allway August 23rd, 2022 Psychedelics, Top News Springfield, Oregon–(Newsfile Corp. – August 23, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) (“Silo Wellness” or the “Company”), a leading global psychedelics company, is pleased to announce that it has opened its first ecotourism microdosing psilocybin resort... Read more
Irwin Naturals Completes Georgia Acquisition, Adds Two Ketamine Clinics to National Chain
August 8, 2022
Ryan Allway August 8th, 2022 Psychedelics, Top News The national chain of psychedelic mental-healthcare clinics growing rapidly LOS ANGELES, Aug. 08, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) completed the acquisition of two ketamine clinics in Georgia through an asset purchase of... Read more
Nirvana Life Sciences Inc. Announces License for a Delivery System for Psychedelic APIs
July 6, 2022
Ryan Allway July 6th, 2022 Psychedelics, Top News VANCOUVER, BC, July 6, 2022 /CNW/ – Nirvana Life Sciences Inc. (Nirvana or the “Company”) (CSE: NIRV), a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing products is pleased to announce it has... Read more
Ryan Allway July 5th, 2022 Psychedelics, Top News Awakn Provides Business Update on Progressing its Lead Program from Phase II b to Phase III Toronto, Ontario–(Newsfile Corp. – July 5, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a revenue-generating biotechnology company researching, developing and... Read more
